112 related articles for article (PubMed ID: 9156242)
21. High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy.
deMagalhaes-Silverman M; Hammert L; Lembersky B; Lister J; Rybka W; Ball E
Bone Marrow Transplant; 1998 Jun; 21(12):1207-11. PubMed ID: 9674853
[TBL] [Abstract][Full Text] [Related]
22. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
24. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
25. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
26. Preoperative high-dose chemotherapy with peripheral blood stem cell support as a primary management of locally advanced breast cancer.
Wang X; Tang J; Wu J; Feng J; Pang L; Dai A; Zheng X
Bone Marrow Transplant; 2001 Feb; 27(3):345-6. PubMed ID: 11277186
[TBL] [Abstract][Full Text] [Related]
27. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.
Koscielniak E; Klingebiel TH; Peters C; Hermann J; Burdach ST; Bender-Götze C; Müller-Weihrich ST; Treuner J
Bone Marrow Transplant; 1997 Feb; 19(3):227-31. PubMed ID: 9028550
[TBL] [Abstract][Full Text] [Related]
28. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
29. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer.
Menichella G; Pierelli L; Scambia G; Salerno G; Benedetti Panici P; Foddai ML; Serafini R; Puglia G; Lai M; Ciarli M
Bone Marrow Transplant; 1994 Dec; 14(6):907-12. PubMed ID: 7536071
[TBL] [Abstract][Full Text] [Related]
30. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC
Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
[TBL] [Abstract][Full Text] [Related]
31. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
[TBL] [Abstract][Full Text] [Related]
33. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study.
Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR
Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
Meehan KR; Verma UN; Cahill R; Frankel S; Areman EM; Sacher RA; Foelber R; Rajagopal C; Gehan EA; Lippman ME; Mazumder A
Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
[TBL] [Abstract][Full Text] [Related]
35. [CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer].
Suwata J; Takada S; Murata N; Ishizuka N; Idezuki Y; Kobayashi M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):83-8. PubMed ID: 9987502
[TBL] [Abstract][Full Text] [Related]
36. [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
Martín M; Casado A; Llorente L; López Martín JA; Rodríguez Lescure A; Nieto Y; Ayala F; Pérez Calvo J; Alonso JL; Pérez López C; Villegas A; Díaz-Rubio E
Med Clin (Barc); 1997 Dec; 109(20):775-81. PubMed ID: 9493155
[TBL] [Abstract][Full Text] [Related]
37. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
[TBL] [Abstract][Full Text] [Related]
38. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
[TBL] [Abstract][Full Text] [Related]
40. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
